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setting of TAVI has been empirically determined, and unfractionated heparin during the procedure followed by dual
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2350hospitalization, and excess costs
(2). Fortunately, these compli-
cations are uncommon (1% to
2% for bleeding; 0.2% for stroke)
after elective PCI.
Transcatheter aortic valve
implantation (TAVI) is a life-
saving procedure for patients
with severe aortic stenosis who
are at very high or prohibitive
risk for standard surgical aortic
valve replacement (SAVR) (3).
However, patients undergoing
TAVI may be at high risk for
both bleeding and stroke. The
incidence of these 2 complica-
tions is at least 10-fold higher for
TAVI compared with PCI: the
30-day risks of major stroke
(w3.5%) and major bleeding/
vascular complications (w10%)portend a formidable challenge for balancing the risks
of embolic and bleeding events in these high-risk patients
(4–19). As with PCI, patients who have bleeding or stroke
after TAVI have greater 30-day and 1-year mortality
(4,20–25). Identifying the targets (pharmacological, me-
chanical) that can improve this balance requires a thorough
understanding of the pathophysiology, clinical risk factors,
timing, and mechanisms involved in embolic and bleeding
complications of TAVI.
The Platelet Colloquium is an annual academic–industry–
governmental scientiﬁc meeting devoted to identifying
research challenges in platelet biology, thrombosis, and
hemostasis and future areas of investigation for improving
patient care. The latest meetings were held in Washington,
DC, on January 20 to 21, 2012, and February 1 to 2, 2013.
This review summarizes the discussions of TAVI, including
the deﬁnition, risks, mechanisms, and timing of stroke and
bleeding, and critically reviews periprocedural and post-
procedural antithrombotic treatment and its potential
inﬂuence on embolic and bleeding complications.TAVI: Deﬁnitions of Stroke and Bleeding
The antithrombotic therapy used during and after TAVI
likely contributes to the occurrence of bleeding and
embolic complications. However, a lack of uniform deﬁni-
tions for periprocedural TAVI complications has made
comparisons among studies difﬁcult. The Valve Academic
Research Consortium has proposed standardized consensus
deﬁnitions for relevant clinical endpoints in TAVI (26).
These deﬁnitions have recently been updated (summarized
in the Online Table) (27) and provide a platform for uni-
formly measuring the impact of proposed antithrombotic
changes.Cerebrovascular Events and TAVI:
Mechanisms, Timing, and Prognostic Value
Cerebral imaging studies have shown a very high incidence
(66% to 86%) of new ischemic defects after TAVI,
irrespective of the transcatheter valve type (balloon- or self-
expandable) or approach (transfemoral, transapical) (28–32).
These defects are usually multiple and distributed in both
vascular territories and cerebral hemispheres, strongly
suggesting an embolic origin. Although most defects are
clinically silent, the incidence of clinically apparent stroke
after TAVI averages about 3% (range 0% to 6%) (Table 1)
(5–9,11,13–16,23,33). In the PARTNER (Placement of
Aortic Transcatheter Valve) trials (17,18), TAVI was asso-
ciated with a higher rate of cerebrovascular events (CVEs
[ischemic stroke or transient ischemic attack]) compared
with either medical treatment/balloon valvuloplasty or
SAVR (Fig. 1) (17,18). The occurrence of periprocedural
stroke has been associated with poorer outcomes at 30 days,
1 year, and 2 years after TAVI (Table 2) (4,23–25,34,35).
Although cerebral emboli can occur anytime during
TAVI, they seem to occur more frequently during posi-
tioning and implantation of the valve prosthesis (36). Thus,
mechanical interactions between the valve prosthesis and the
calciﬁed native valve appear to play an important role in
these events. The degree of valve calciﬁcation correlates well
with aortic stenosis severity (37), and patients with smaller
valve areas are at higher risk of CVEs within 7 days after
TAVI (24). In addition, the use of the ﬁrst version of
delivery catheters (22-F and 24-F, without nosecone) in the
PARTNER trial might have contributed to the high rate of
CVEs observed (17,18). Balloon post-dilation of the valve
prosthesis for treatment of signiﬁcant paravalvular leaks,
repeated device implantation attempts, and valve prosthesis
dislodgment/embolization have also been associated with
higher rates of CVEs, mainly within 24 h after TAVI
(25,35). These mechanical phenomena provide a rationale
for future technology modiﬁcations, in particular embolic
protection devices, to minimize cerebral embolization during
valve prosthesis deployment (38–40).
Despite the recognized early risk, about half of all peri-
procedural CVEs occur >24 h after TAVI (Fig. 2)
(25,33,35,41–43). Although later CVEs can reﬂect eventual
embolization of atheromatous material partly mobilized by
the delivery catheter, mechanisms besides or in addition to
prosthesis manipulation are likely involved in a substantial
number of these events. Several factors might contribute to
ongoing thrombogenicity of the valve apparatus after
implantation, including hemostatic activation due to vessel-
wall disruption or artiﬁcial surface exposure, and ﬂow
turbulence through the valve oriﬁce (44). Because both the
balloon- and self-expandable transcatheter valve systems are
stented, exposure of the stent struts to the circulation might
trigger initiation of the coagulation cascade and/or platelet
activation. The presence of a paravalvular space occupied by
the native aortic valve might also be associated with some
Table 1 Ischemic and Bleeding Outcomes at 30 Days and 1 Year in Large TAVI Registries
European
(8)
(n ¼ 646)
Canadian
(5)
(n ¼ 339)
SOURCE
(6,7)
(n ¼ 1,038)
Italian
(23)
(n ¼ 663)
FRANCE
(9)
(n ¼ 244)
Belgian
(11)
(n ¼ 328)
FRANCE-2
(16)
(n ¼ 3,195)
SOURCE XT
(13)
(n ¼ 2,706)
ADVANCE
(14)
(n ¼ 1,015)
ANZ
(15)*
(n ¼ 428)
30 days
Vascular complications d 13.0%y 12.8%z d 7.3% d d d d 12.6%x
Major d d 7.0% 2.0% d d d 6.0%x 10.7% 4.0%
Minor d d 5.5% d d d d d d 8.9%
Bleeding d d d d d d d d d 23.1%
Life-threatening/
disabling
d d d d d d d d 4.0% 4.7%
Major d d d d d d d 7.2% 9.7% 8.9%
Minor d d d d d d d d d 12.9%
Stroke 1.9% 2.3% 2.5% 1.2% 3.6% 5% 3.4% 2.2% 2.9% 3.6%
Major d d d d d d 1.9% d 1.2% d
Minor d d d d d d 1.5% d 1.7% d
1 year
Vascular complications d d d d d d d d d d
Major d d d d d d 4.7% d d d
Minor d d d d d d 5.0% d d d
Bleeding d d d d d d 13.1% d d d
Life-threatening/
disabling
d d d d d d 1.2% d d d
Major d d d 3.2% d d 4.5% d d d
Minor d d d d d d 7.4% d d d
Stroke d d 4.5% 2.5% d d 4.1% d d 5.3%
*Preliminary data as of May 2012; enrollment of the 900 targeted patients is expected to be complete in June 2016 (NCT01015612). yAccess site complications. zLimb-threatening ischemia, vessel rupture
requiring additional unplanned vascular surgery, or additional interventional treatment. xUsing Valve Academic Research Consortium deﬁnition.
ANZ ¼ Australia-New Zealand; FRANCE ¼ French Aortic National CoreValve and Edwards Registry; SOURCE ¼ SAPIEN Aortic Bioprosthesis European Outcome Registry; TAVI ¼ transcatheter aortic valve
implantation.
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2351degree of blood stasis, leading to a prothrombotic environ-
ment and resulting risk for thromboembolic events.
Recent studies suggest that new atrial arrhythmias are
associated with a higher rate of CVEs after TAVI, especially
for events occurring between 24 h and 30 days after the
procedure (35,42,43). The interaction between existing atrial
ﬁbrillation and post-TAVI stroke has been recently
emphasized in the ADVANCE CoreValve registry (14), in
which a history of atrial ﬁbrillation increased the risk of
stroke/transient ischemic attack after TAVI by 2.2-fold.
Nombela-Franco et al. (35) also showed an increased risk of
cerebrovascular events after a mean follow-up of 1 year after
TAVI in patients with chronic atrial ﬁbrillation.
The incidence of ischemic stroke >30 days after TAVI
(w2% per year) is similar to that observed after SAVR and
medical treatment in similar populations of elderly and high-
risk patients with severe aortic stenosis, allaying initial
concerns of a potential late prothrombotic effect associated
with transcatheter valves (4,17,18,45). A PARTNER sub-
study showed that a higher atherosclerotic burden and
previous CVE were the factors most strongly associated with
late CVEs after TAVI (24). Nombela-Franco et al. (35)
found that peripheral vascular disease, previous CVE, and
chronic atrial ﬁbrillation were the main predictors of late
CVEs after TAVI. On the other hand, the incidence of
hemorrhagic stroke beyond 30 days in PARTNER was
higher in the TAVI group than in the medical treatmentgroup (45), highlighting the delicate balance of antith-
rombotic treatment after TAVI in the elderly. Unfortu-
nately, no data were provided regarding antithrombotic
treatment among patients suffering from hemorrhagic stroke
during follow-up; this important point must be clariﬁed in
future studies.Bleeding Complications and TAVI:
Mechanisms, Timing, and Prognostic Value
The Valve Academic Research Consortium group classiﬁes
bleeding events after TAVI as minor, major, or life-
threatening (Online Table) (26,27). On the basis of the
Valve Academic Research Consortium deﬁnitions, the rates
of major and life-threatening bleeding in the periprocedural
period have been as high as 15% to 32% and 5% to 16%,
respectively (17,18,46–49). The incidence of major bleeding
in the largest non-U.S. registries (5–9,11,13–16,23) and the
PARTNER trials (17,18) are summarized in Table 1 and
Figure 3, respectively.
The cause of bleeding may be partly mechanical. The use
of large delivery catheters (larger than 20-F in the initial
TAVI experience, 18-F afterward) has been associated with
a high rate (>10%) of major vascular complications
(3,17,18,46–49), which may in turn be associated with
signiﬁcant, clinically overt internal bleeding. In addition,
patients undergoing TAVI are elderly and often have
Figure 1 Cerebrovascular Events in the PARTNER Trial
Cerebrovascular events in the PARTNER (Placement of Aortic Transcatheter Valve) A and B trial cohorts (17,18) randomized to receive transcatheter aortic valve intervention
(TAVI) (open bars) versus either surgical aortic valve replacement (SAVR) (cohort A) or medical treatment (Cohort B) (solid bars). Adapted from Hynes et al. (33). TIA = transient
ischemic attack.
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2352diseased iliofemoral arteries. Accordingly, a higher sheath/
femoral artery ratio and greater arterial calciﬁcation have
been identiﬁed as important predictors of major vascular
complications in transfemoral TAVI (50). The use of
percutaneous closure devices also has been associated with an
important “learning curve” processdincreased experience
with these devices has translated into reduced vascular and
bleeding complications (51). Similarly, in patients under-
going TAVI by the transapical approach, major/life-
threatening bleeding is usually associated with mechanical
myocardial tears occurring during surgical repair of the apex
(52). Two recent studies found the transapical approach to
be the most important predictor of life-threatening bleeding
after TAVI (53,54).
Not all bleeding complications are mechanical in origin.
A signiﬁcant proportion of patients undergoing TAVI
receive post-procedural blood transfusions despite having
no obvious source of bleeding or having bleeding not
directly related to the procedure (typically genitourinary or
gastrointestinal) (48,55). In addition, as many as 50% of
patients undergoing TAVI have some degree of anemia atTable 2 Relation Between Periprocedural Stroke a
First Author (Ref. #) n Timing
Kodali (4) 348 2 yrs U
Tamburino (23) 663 1 yr M
Miller (24) 344 1 yr U
Stortecky (25) 389 30 days U
Eggebrecht (34) 10,037 30 days M
Nombela-Franco (35) 1,061 30 days M
1 yr M
CI ¼ conﬁdence interval; HR ¼ hazard ratio; NR ¼ not reported; OR ¼ oddsbaseline (56), which may predispose to bleeding complica-
tions and a tendency to transfuse packed red blood cells even
with no overt bleeding (57). Regardless of the mechanism,
however, major/life-threatening bleeding is associated with
greater acute and midterm mortality after TAVI (Table 3)
(4,20–22,53,56).
Current Recommendations for
Antithrombotic Therapy During and After TAVI
The current recommendations for antithrombotic treatment
in the setting of TAVI are shown in Table 4. Unfractionated
heparin has been the most common anticoagulant used
during TAVI. In the PARTNER trials (17,18), procedural
parenteral anticoagulation therapy consisted of a 5,000 IU
bolus of unfractionated heparin followed by additional
boluses to maintain an activated clotting time 250 s.
Recently, the American College of Cardiology Foundation/
American Association for Thoracic Surgery/Society for
Cardiovascular Angiography and Interventions/Society
of Thoracic Surgeons (ACCF/AATS/SCAI/STS) expertnd Mortality After TAVI
Analysis
OR/HR for Mortality
(95% CI) p Value
nivariate 2.47 (1.42–4.30) <0.001
ultivariate 15.76 (3.27–75.9) 0.001
nivariate w2.00 NR
nivariate 11.7 (3.40–40.3) <0.001
eta-analysis w3.7 NR
ultivariate 7.43 (2.45–22.53) 0.001
ultivariate 1.75 (1.01–3.04) 0.043
ratio; TAVI ¼ transcatheter aortic valve implantation.
Figure 2 Timing of Cerebrovascular Events After TAVI
Timing of cerebrovascular events (CVE) within 30 days after transcatheter aortic
valve intervention (TAVI): transient ischemic attack (orange), minor stroke (green),
or major stroke (blue). Adapted from Nombela-Franco et al. (35).
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2353consensus document on TAVI recommended maintenance
of an activated clotting time >300 s (58). This document
also stated that heparin anticoagulation could be reversed
by administration of protamine sulfate at a milligram-to-
milligram neutralization dose.
After TAVI, dual antiplatelet therapy (DAPT) with
aspirin (80 mg to 325 mg daily) and clopidogrel (75 mg daily)
has been used in most centers and studies. However, the
use of a loading dose of clopidogrel (300 mg to 600 mg)
before TAVI is usually not speciﬁed, and the duration of
clopidogrel therapy has varied widely among studies (usually
1 to 6 months). Importantly, recommendations forFigure 3 Major Bleeding Events in the PARTNER Trial
Incidence of major bleeding in the PARTNER (Placement of Aortic Transcatheter Valve) trial,
valve intervention (TAVI) (open bars) versus either surgical aortic valve replacement (SAVantithrombotic treatment were not established prospectively
in most of the largest national or industry-driven registries
(5–9,11,13–16,23). In the PARTNER trial (17,18), the
recommendation was to use aspirin (75 mg to 100 mg
per day) for life and clopidogrel (75 mg per day) for 6 months,
with a 300-mg loading dose if the patient was not already
taking clopidogrel. The ACCF/AATS/SCAI/STS panel
recommends DAPTwith aspirin and clopidogrel after TAVI
to reduce the risk of thrombotic or thromboembolic events,
but its duration and the use of a loading dose of clopidogrel
are not speciﬁed (58). The recent Canadian Cardiovascular
Society statement on TAVI recommends the use of aspirin
indeﬁnitely and clopidogrel for 1 to 3 months (59).
About one-third of patients undergoing TAVI will
already be receiving an oral anticoagulant, typically warfarin
for chronic atrial ﬁbrillation. For these patients, there has
been a lack of uniformity regarding the choice of post-
procedural antithrombotic treatment. They have, therefore,
received either triple antithrombotic therapy (warfarin with
aspirin and clopidogrel), warfarin with 1 antiplatelet drug
(aspirin or clopidogrel), or warfarin alone after TAVI,
at their physicians’ discretion. There are currently no data
on the use of new anticoagulants, such as the direct
thrombin or factor Xa inhibitors, in this population. In the
PARTNER trial, there was no speciﬁc recommendation for
either the periprocedural or later anticoagulation manage-
ment of this increasingly prevalent patient population
(17,18). The ACCF/AATS/SCAI/STS expert consensus
recommends that low-dose aspirin be continued, but that
other antiplatelet therapy be avoided whenever possible
(58). The use of triple antithrombotic therapy is likewise
discouraged in the Canadian Cardiovascular Society state-
ment on TAVI (59).(left) cohort A and (right) cohort B (17,18) randomized to receive transcatheter aortic
R) (cohort A) (solid bars) or medical treatment (cohort B) (solid bars).
Table 3 Relation Between Periprocedural Major or Life-Threatening Bleeding and Mortality After TAVI
First Author (Ref. #) n Severity of Bleeding Timing Analysis
OR/HR for Mortality
(95% CI) p Value
Kodali (4) 348 Major bleeding 2 yrs Univariate 2.11 (1.41–3.17) <0.001
Halliday (20) 101 Life-threatening In-hospital Univariate 19.07 (2.72–133.7) 0.006
6 months Univariate 7.50 (1.15–48.6) <0.05
Van Mieghem (21) 986 Life-threatening 30 days Univariate 5.65 (3.15–10.1) <0.05
30 days Multivariate 4.85 (2.45–9.62) <0.05
Ussia (22) 181 LTþM 30 days Univariate 9.27 (2.54–33.9) 0.001
3 yrs Univariate 4.04 (1.85–8.80) <0.001
Borz (53) 250 Life-threatening 1 yr Multivariate 2.54 (1.30–4.90) 0.002
Nuis (56) 995 Life-threatening 30 days Multivariate 6.65 (2.28–19.44) 0.001
LTþM ¼ life-threatening plus major; other abbreviations as in Table 2.
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2354Options for improving TAVI-related antithrombotic
therapy and procedural strategies. MECHANICAL FACTORS.
Decreasing the size of TAVI delivery catheters has already been
associated with reduced vascular access site complications
(21,60). Future reductions in sheath sizes may be associated
with additional reductions in vascular complications, which in
turn will likely be associated with reduced severe bleeding
events. In addition, improvements in both the use of percuta-
neous closure devices and management of vascular complica-
tions will reduce the rate and impact of vascular complications
during TAVI (51,55,61,62). Similarly, mechanical reﬁnements
may prove important for reducing procedural embolic events.
Three embolic protection devices have been used duringTAVI:
2 deﬂector devices (Embrella device, Edwards Lifesciences
Inc., Irvine, California; and SMT Embolic Deﬂection Device,
SMT Research and Development Ltd., Herzliya, Israel) and 1
ﬁlter device (Claret dual ﬁlter system, Claret Medical Inc.,
Santa Rosa, California). First-in-human studies have proven
the feasibility of using these devices during TAVI (38–40),
but future randomized studies will be required to evaluate
their efﬁcacy in reducing CVEs.
ANTICOAGULATION THERAPY DURING TAVI. Procedural
bleeding may be decreased by using alternative parenteral
anticoagulants, such as the intravenous direct thrombin
inhibitor bivalirudin. Bivalirudin has been shown to reduce
the rate of bleeding while not increasing ischemic events
during PCI (63). Bivalirudin also was associated withTable 4 Current Recommendations for Antithrombotic Agents and S
PARTNER Trial (17,18) ACC/STS R
Pre-procedural Aspirin 80 mg
Clopidogrel 300 mg
Procedural Unfractionated heparin Unfractionated
Goal ACT: 250 s Goal ACT: 300
Reversal with protamine optional Reversal with
Bivalirudindnot allowed? Bivalirudindn
Post-procedural (ﬁrst 30 days) Aspirin 81 mg/day indeﬁnitely þ Aspirin 81 mg
Clopidogrel 75 mg/day  90 days Clopidogrel 75
If warfarin ind
clopidogrel
ACC ¼ American College of Cardiology; ACT ¼ activated clotting time; AF ¼ atrial ﬁbrillation; CCS ¼ Can
valve implantation.reduced major bleeding in patients undergoing balloon val-
vuloplasty (64). Although bivalirudin might prove useful
during TAVI, life-threatening vascular and bleeding
complications occurring during the procedure, such as
cardiac tamponade, aortic annulus rupture, or peripheral
vascular rupture, often require immediate reversal of anti-
coagulation, which is not easily achieved with bivalirudin. A
prospective pilot study evaluating the usefulness of bivalir-
udin in TAVI is ongoing (BRAVO [Effect of BivaliRudin
on Aortic Valve Intervention Outcomes] trial) (64).
Protamine has typically been used to reverse unfractionated
heparin anticoagulation after TAVI, especially following
a transapical or transaortic approach. Although the purpose
of giving protamine at the end of the procedure is to reduce
bleeding related to access closure, a prothrombotic effect of
the protamine leading to an increase in CVEs cannot be
excluded (65–67). The safety of reversing heparin effects after
TAVI must therefore be systematically evaluated. Strategies
for reversibility could be further explored with newer agents:
a reversible ribonucleic acid aptamer factor IX inhibitor
(pegnivacogin and anivamersen [REG1 Anticoagulant
System, Regado Biosciences, Baskin Ridge, New Jersey])
has been studied in the RADAR (A Randomized, Partially
Blinded, Multicenter, Active-Controlled, Dose-Ranging
Study Assessing the Safety, Efﬁcacy, and Pharmacodynamics
of the REG1 Anticoagulation System in Patients with
ACSs) trial in coronary intervention (68). The potential of
this reversible anticoagulant approach may be of addedtrategies for TAVI
ecommendations (58) CCS Statement (59)
d d
heparin d
s
protamine recommended
ot mentioned
/day indeﬁnitely þ Indeﬁnite low-dose aspirin generally recommended þ
mg/day  3–6 months Thienopyridine  1–3 months
icated (AF), then no If oral anticoagulant indicated (AF), avoid triple
therapy unless deﬁnite indication exists
adian Cardiovascular Society; STS ¼ The Society for Thoracic Surgeons; TAVI ¼ transcatheter aortic
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2355importance in procedures such as TAVI that employ large
sheaths with higher bleeding risks.
Post-Procedural Strategies
The risk of thromboembolic events after TAVI is highest
within the ﬁrst days (24,33,35,41). These ﬁndings agree
with studies showing that the risk of thromboembolic events
is highest within 3 months after surgical bioprosthetic valve
implantation (69). For surgical bioprosthetic valves, the
general recommendation is to use aspirin for 3 months
(44,70); however, some data suggest a similar incidence of
thromboembolic events regardless of aspirin use after bio-
logical aortic valve replacement (71). Recently, Brennan
et al. (72) evaluated the risks and beneﬁts of short-term
anticoagulation in 25,656 patients who had received an
aortic valve bioprosthesis. Compared with aspirin only,
aspirin plus warfarin was associated with reduced risks of
death and embolic events, but at the cost of an increased
bleeding risk. Mérie et al. (73,74) also showed a reduced
risk of thromboembolic events and cardiovascular death
associated with warfarin treatment within 6 months after
bioprosthetic aortic valve surgery.
The DAPT hypothesis. The current post-TAVI recom-
mendations are based on an understanding of ischemic events
after PCIdnamely, the use of DAPT to obviate the stent-
mediated risk of thrombosis/embolization. Unfortunately,
data are lacking to indicate whether presumed thromboem-
bolic events after TAVI are primarily due to platelet-based
or thrombin-based clot formation. A clearer mechanistic
understanding of the pathobiology of thromboembolic events
during and after TAVI will provide a translatable foundation
for optimal therapies. Long-term data from bioprosthetic
valve studies indicate that neointimal tissue growth and
endothelialization of the valve stent probably occur about
3 months after implantation, when the risk of stroke shows
a corresponding reduction (73). Similarly, histopathological
studies of the CoreValve apparatus show a similar timeline
for the incorporation and endothelialization of the trans-
catheter valve (75). Thus, the critical period for future clinical
investigation of pharmacologic stroke prevention is likely
between 24 h and 3 months post-TAVI.
The DAPT hypothesis for preventing stroke after TAVI
must be tested. A small randomized study of 79 patientsTable 5
Current ACC/AHA, ACCP, and ESC Guideline Recommendat
After Bioprosthetic Valve Replacement
Bioprosthesis ACCP
AVR, low risk (sinus rhythm) ASA 50–100 mg/d
Warfarin INR: 2.0–3.0 (Class IIay)
AVR, high riskx ASA 75–100 mg/d (Class I*)
Warfarin INR: 2.0–3.0 (Class I*)
*Class I: conditions for which there is evidence for and/or general agreement that the procedure or t
usefulness/efﬁcacy. zGrade 2c: weak recommendation based on low quality of evidence. xAmerican He
embolism, and hypercoagulable condition; American College of Chest Physicians (ACCP) risk factors: at
ACC ¼ American College of Cardiology; ASA ¼ acetylsalicylic acid (aspirin); AVR ¼ aortic valve replacem
antagonists.showed no differences in ischemic and bleeding complica-
tions between aspirin alone and aspirin with clopidogrel after
TAVI, but the limited sample size precluded to drawing
any deﬁnitive conclusions regarding efﬁcacy and safety (76).
The ongoing ARTE (Aspirin Versus Aspirin þ Clopidogrel
Following Transcatheter Aortic Valve Implantation) pilot
trial (NCT01559298) is comparing these 2 regimens and
should provide additional information to support a future
larger, more deﬁnitive study (77). The importance of DAPT
in preventing stroke is especially questionable in light of
a recent trial in non-TAVI patients: the use of aspirin plus
clopidogrel versus aspirin alone to prevent future lacunar
infarcts was associated with higher mortality, no reduction in
future strokes, and more bleeding complications (78). The
use of novel, more potent antiplatelet agents such as tica-
grelor also might merit consideration as monotherapy or in
combination with low-dose (<100 mg daily) aspirin.
The antithrombin hypothesis. TAVI involves placement
of a bioprosthetic heart valve; surgical aortic valve bio-
prosthetic valve replacement may or may not beneﬁt from
routine warfarin anticoagulation (79). Although mechanical
valves are clearly more prothrombotic, there is a concern that
bioprosthetic valves may have a potential for thrombus
formation during the ﬁrst 3 months after implantation (69).
The current controversy over best anticoagulation practices
for surgical aortic valve replacement is summarized in
Table 5. While it is tempting to extend the antithrombin–
heart valve hypothesis to the novel oral anticoagulants, this
may not be truedrecently, the RE-ALIGN (Randomized,
Phase II Study to Evaluate the Safety and Pharmacokinetics
of Oral Dabigatran Etexilate in Patients After Heart
Valve Replacement) trial comparing dabigatran to warfarin
for patients with mechanical heart valves was terminated
because of adverse safety events related to dabigatran (80,81).
Thus, any future trials of novel oral anticoagulants in the
realm of bioprosthetic valves and TAVI require caution.
Is there further support for a focus on antithrombin
therapies after TAVI? Most ischemic events after TAVI are
cerebrovascular, and, as discussed, atrial arrhythmias might
play an important role in their occurrence (14,35,42,43).
Indeed, the cardioembolic risk of patients undergoing TAVI
is very high (mean CHADS [congestive heart failure,
hypertension, age 75 years, diabetes mellitus, prior stroke
or transient ischemic attack] score w3) (35,42). Therefore,ions for Antithrombotic Therapy Within 3 Months
ACC/AHA ESC
ASA 75–100 mg/d (Class I*) VKA (target INR: 2.5)
VKA (Grade 2cz)
VKA as per AF guidelines No separate recommendation
reatment is beneﬁcial, useful, and effective. yClass IIa: weight of evidence/opinion is in favor of
art Association (AHA) risk factors: atrial ﬁbrillation, left ventricular dysfunction, previous thrombo-
rial ﬁbrillation (AF). Adapted from Whitlock and Eikelboom (79).
ent; ESC ¼ European Society of Cardiology; INR ¼ international normalized ratio; VKA ¼ vitamin K
Table 6 Possible Future Antithrombotic Strategies for TAVI That Have Not Yet Been Evaluated
Potential Advantages Potential Disadvantages
Procedural
Bivalirudin Predictable antithrombotic response; can be used in heparin-induced
thrombocytopenia.
Quick onset of action; short half-life. Not reversible with protamine.
Argatroban Can be used in heparin-induced thrombocytopenia or renal dysfunction
(metabolized by liver).
Longer half-life than bivalirudin and requires 1–3 h to achieve steady-state.
Aptamers Completely reversible; partly reversible. Modest experience in PCI to date.
Post-procedural
Apixaban or
rivaroxaban
More rapid onset and predictable levels of anticoagulation as
compared with warfarin.
No antidote.
Dabigatran More rapid onset and predictable levels of anticoagulation as
compared with warfarin.
No antidote. Twice daily dosing.
Prasugrel More rapid onset, higher degrees of platelet inhibition, and less
interpatient variability as compared with clopidogrel.
Unknown if higher degrees of platelet inhibition are beneﬁcial post-TAVI.
Contraindicated in patients with history of stroke or TIA.
Ticagrelor More rapid onset, higher degrees of platelet inhibition, and less
interpatient variability as compared with clopidogrel.
Unknown if higher degrees of platelet inhibition are beneﬁcial post TAVI.
Twice daily dosing. Dyspnea.
AF ¼ atrial ﬁbrillation; CHADS2¼ congestive heart failure, hypertension, age 75 years, diabetes mellitus, prior stroke or transient ischemic attack; PCI¼ percutaneous coronary intervention; TIA ¼ transient
ischemic attack; TAVI ¼ transcatheter aortic valve implantation.
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2356the use of short-term anticoagulation might play a role in
reducing ischemic events after TAVI. Chronic atrial ﬁbril-
lation is present in w30% of patients undergoing TAVI,
and the global rate of atrial arrhythmias increases to w40%
to 50% when new atrial ﬁbrillation after the procedure is
considered, further highlighting the potential importance of
anticoagulation therapy after TAVI.
The challenge in managing patients with atrial ﬁbrillation
undergoing TAVI has translated into high variability
regarding antithrombotic therapy, ranging from triple therapy
(warfarin, aspirin, and clopidogrel) to warfarin alone. The
incidence of major adverse cardiovascular events and bleeding
after TAVI according to antithrombotic regimen was evalu-
ated in a German registry of 1,450 patients (82). In all, 7%
received aspirin or clopidogrel monotherapy, 11% received
aspirin or clopidogrel combined with an oral anticoagulant,
66% of the patients received DAPT, and 16% received triple
therapy with aspirin, clopidogrel, and an oral anticoagulant
agent. After multivariate adjustment, the use of triple therapy
was associated with an increased risk of the composite of
death, stroke, embolism, or major bleeding (adjusted odds
ratio, 1.78; 95% conﬁdence interval [CI]: 1.1 to 2.9).
Given the previously mentioned lack of data to support
DAPT regimens after TAVI, aspirin and warfarin or
warfarin alone may be the most effective and safe approach
to anticoagulation in post-TAVI patients with underlying
atrial ﬁbrillation. Even this fairly simple recommendation
needs further investigation; in the WOEST (What Is the
Optimal Antiplatelet and Anticoagulant Therapy in Patients
With Oral Anticoagulation and Coronary Stenting?) trial,
clopidogrel with warfarin was superior to triple therapy in
patients with atrial ﬁbrillation undergoing drug-eluting stent
placement (including a striking decrease in all-cause
mortality associated with clopidogrel/warfarin [hazard
ratio: 0.39; 95% CI: 0.16 to 0.93]) (83,84). Whether a post-
TAVI regimen of clopidogrel and warfarin among patients
with known atrial ﬁbrillation can be recommended overaspirin and warfarin requires further investigation in this
high-risk population.
Future Investigations
Future investigations should focus on 2 separate arenas:
procedural and post-procedural antithrombotic therapy. We
summarize potential areas of investigation as follows:
 Procedural anticoagulation trials should compare
regimens that have the potential to limit bleeding
complications (aptamer technology, bivalirudin)
compared with the current standard of care (heparin).
 Studies should fundamentally question the DAPT
versus antithrombin hypotheses for post-procedural
antithrombotic treatment, especially in groups at
highest risk for subsequent embolic events.
 Although the rate of thromboembolic events after
TAVI is clinically important, it is also low enough to
make clinical endpoint trials challenging. We suggest
that surrogate endpoint trials (serial brain imaging)
might allow meaningful trial designs without pro-
longed enrollment.
 A summary of the potential advantages and disad-
vantages of newer antiplatelet and anticoagulant agents
during and after TAVI is shown in Table 6.
 Finally, future developments in antithrombotic therapy
for TAVI may come from novel molecular targets.
Agents that target thrombin receptor signaling have
been studied in patients undergoing PCI and in acute
coronary syndromes, and the collagen receptor glyco-
protein VI may be a useful diagnostic marker for clin-
ical outcomes and a potential therapeutic target (85).
Conclusions
The clinical and demographic characteristics of patients
undergoing TAVI pose unique challenges for developing
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2357and implementing optimal antithrombotic therapy. The
procedural risks of ischemic stroke and major bleeding
remain high, and both of these complications continue to
occur throughout the ﬁrst month after the procedure. The
goal in clinical practice is to develop, test, and implement an
antithrombotic regimen for the periods of highest
riskdduring and within 30 days after the procedure. Our
current practice of DAPT for 6 months after TAVI is
empirical and may not adequately address the importance of
atrial ﬁbrillation in post-TAVI embolic events. As the ﬁeld
of antiplatelet and novel anticoagulants continues to expand,
the number of potential drug combinations and comparator
groups will increase exponentially. Given the frail, high-risk
nature of TAVI patients, uncontrolled registry studies of
more potent antithrombotic strategies will not sufﬁce.
Carefully crafted and conducted randomized trials will be
the best means to balance the efﬁcacy and risks of anti-
coagulation therapy for the vulnerable patients undergoing
TAVI.
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